United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $568.81, for a total transaction of $5,403,695.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at $23,044,199.53. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
United Therapeutics Trading Up 0.4%
Shares of UTHR stock opened at $569.11 on Wednesday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The company has a market capitalization of $24.94 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75. The firm has a fifty day simple moving average of $540.11 and a 200-day simple moving average of $496.38.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the firm posted $6.19 EPS. The firm's revenue was up 7.4% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 27.97 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $31,000. Wilmington Savings Fund Society FSB increased its holdings in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $48,000. 94.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have commented on UTHR shares. TD Cowen increased their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research note on Thursday, March 12th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Bank of America raised their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. Finally, Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $601.50.
Get Our Latest Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
